I lead the development and commercialization of innovative diagnostic products for liver diseases based on a proprietary glycoproteomic biomarker technology. I joined Glycotest as the first employee to create and execute the business plan that has attracted world-class clinical collaborators, and secured financing from strategic and financial investors and a licensee for the huge Chinese liver disease market. I completed enrollment of a 20-site / >1400-patient clinical validation study and closed a development and licensing option deal with the University of Georgia. Prior to Glycotest, I led drug development programs in startup, pre-commercial and revenue-stage companies for over 10 years, and continue to advise EMV Capital plc, Glycotest's majority investor, on drug development initiatives.As an entrepreneurial executive, I am passionate about acquiring command of new technologies and products, identifying compelling commercial opportunities, and developing and executing strategic plans. I have a record of meeting ambitious clinical, manufacturing, and regulatory milestones, have been an executive team member on private financing, partnering, IPO, M&A, turnaround, IP acquisition, and spin-out initiatives, and am an experienced negotiator of agreements for product and technology acquisition, development and commercialization. I have also invented and licensed a commercialized manufacturing process, invented two products advanced to clinical development, am an inventor on 27 issued US patents with foreign equivalents, and have authored 50 peer-reviewed publications.